首页> 外文OA文献 >Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

【2h】

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

机译：第3阶段遗产研究的最终总体存活分析证明了在HER2阳性转移性乳腺癌中的曲妥珠单抗至曲妥珠单抗的等价性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Hope S. Rugo; Eduardo J. Pennella; Unmesh Gopalakrishnan; Miguel Hernandez-Bronchud; Jay Herson; Hans Friedrich Koch; Subramanian Loganathan; Sarika Deodhar; Ashwani Marwah; Alexey Manikhas; Igor Bondarenko; Guzel Mukhametshina; Gia Nemsadze; Joseph D. Parra; Maria Luisa T. Abesamis-Tiambeng; Kakhaber Baramidze; Charuwan Akewanlop; Ihor Vynnychenko; Virote Sriuranpong; Gopichand Mamillapalli; Sirshendu Roy; Eduardo Patricio Yanez Ruiz; Abhijit Barve; Adolfo Fuentes-Alburo; Cornelius F. Waller;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer [J] . Rugo Hope S., Pennella Eduardo J., Gopalakrishnan Unmesh, Breast cancer research and treatment. . 2021,第2期

机译：第3阶段遗产研究的最终总生存率分析证明了在HER2阳性转移性乳腺癌中的曲妥珠单抗至曲妥珠单抗的等价性
2. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial [J] . Krop Ian E., Kim Sung-Bae, Gonzalez Martin Antonio, The lancet oncology . 2017,第6期

机译：Trastuzumab与先前治疗Her2阳性转移性乳腺癌患者的医生选择的Emtansine（Th3RESA）：随机开放标签阶段3试验的最终整体生存结果
3. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial [J] . Krop Ian E., Kim Sung-Bae, Gonzalez Martin Antonio, Journal of Turbulence . 2017,第6期

机译：Trastuzumab与先前治疗Her2阳性转移性乳腺癌患者的医生选择的Emtansine（Th3RESA）：随机开放标签阶段3试验的最终整体生存结果
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised open-label phase 3 trial [O] . Véronique Diéras, David Miles, Sunil Verma, -1

机译：曲妥珠单抗Emtansine与卡培他滨加拉帕替尼治疗先前治疗过的HER2阳性晚期乳腺癌（EMILIA）的患者：一项随机开放标签的3期临床试验的最终总体生存率的描述性分析
7. Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety Study [O] . Sherko Kümmel, Carlo Alberto Tondini, Jacinta Abraham, 2020

机译：皮下曲妥珠单抗与腹膜腹和多西紫杉醇在Her2阳性转移性乳腺癌中：最终对选手的分析，一个相3B单臂安全研究

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

著录项

相似文献

相关主题

期刊订阅